DIRS.INFO The most relevant business & tech news

☆ Brain science start-up Neuroelectrics uses electricity and a headcap to reduce seizures in patients with epilepsy. Now it needs FDA approval
▼ + stars: | 2024-06-14 | by ( Cristy Garratt Maria Gomez De Sicart | Cristy Garratt | Https | ) www.cnbc.com time to read: +1 min

High up in the hills of Barcelona, brain science start-up Neuroelectrics is developing therapies that it says will improve the lives of people living with brain disease. Its main product is a headcap, which monitors the brain's electrical activity and stimulates regions of the brain with mild electrical currents. Co-founder and CEO Ana Maiques believes it will significantly improve the lives of people suffering with epilepsy. In addition to epilepsy, Maiques and her team are optimistic that the headgear can also be used to treat depression and Alzheimer's. So, when you have epilepsy, you have an electrical discharge in one area of your brain, so they can really target and help them," said Roser Sanchez-Todo, R&D director for Neuroelectrics' brain modelling department.

Persons: Ana Maiques, Maiques, Roser Sanchez, Neuroelectrics Organizations: CNBC Tech, U.S . Food, Drug Administration Locations: Barcelona

☆ Apple jumps to a new high after AI unveil — plus, our latest thinking on 6 more portfolio stocks
▼ + stars: | 2024-06-11 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. "Notice where Stanley Black & Decker is when you have a good day for the bonds," Jim Cramer pointed out. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, you'll, Stanley Black, Decker, Dupont, Ed Breen, Jim, Eli Lilly, Eli Lilly Alzheimer's, Banks, Wells, Michael Santomassimo, Santomassimo, Morgan Chittum, We've, Tom Jorden, Coterra, Jorden, Jerome Powell, Jim Cramer's Organizations: CNBC, Longtime, Apple, Treasury, Club, DuPont, GE Healthcare, Huntington, Investing Club, Coterra Energy, Broadcom, VMware, Jim Cramer's Charitable

☆ Here's an undervalued stock that can benefit from new Alzheimer's drugs
▼ + stars: | 2024-06-11 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Financials, Morgan Stanley, Wells, —, Jim, Eli Lilly, Biogen, Jim Cramer's, LLY, DOV Organizations: CNBC, Federal, GE Healthcare, FDA, GE, JPMorgan, Dover Locations: That's, Dover

☆ Stocks making the biggest moves premarket: Eli Lilly, General Motors, Shopify
▼ + stars: | 2024-06-11 | by ( Samantha Subin | ) www.cnbc.com time to read: +2 min

Eli Lilly — Eli Lilly shares rose 2% after a panel of FDA advisors recommended the approval of its Alzheimer's drug known as donanemab. General Motors — The automaker's stock added more than 1% after its board authorized a $6 billion stock buyback program . Shopify — The e-commerce stock rose about 1% after JPMorgan initiated coverage with an overweight rating. Apple — Apple shares slipped less than 1% a day after the iPhone maker's Worldwide Developers Conference, where it revealed its artificial intelligence plans , called Apple Intelligence. GameStop — GameStop shares slipped 1% before the bell, continuing its volatile ride.

Persons: Eli Lilly, General Motors, Siri, Keith Gill's, Lee Cole, —, Jesse Pound, Sarah Min Organizations: General, JPMorgan, Apple, Apple Intelligence, Technology, Reuters, Apollo, Kyndryl Holdings, GameStop, Calavo, —, Calavo Growers

☆ Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug
▼ + stars: | 2024-06-11 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Tuesday explained why he continues to be bullish about pharmaceutical giant Eli Lilly . Continually confident about Eli Lilly because of the enormous success of its weight loss and diabetes drugs, he said the company's new Alzheimer's treatment has the potential to further boost business. On Monday, a panel of advisors to the Food and Drug Administration unanimously recommended Eli Lilly's Alzheimer's drug, currently known as donanemab. "I think this advisory committee decision on their Alzheimer's drug does precisely that." Eli Lilly did not immediately respond to request for comment.

Persons: CNBC's Jim Cramer, Eli Lilly, Eli Lilly's, it's, Cramer, they've Organizations: Food and Drug Administration, FDA Locations: U.S, Biogen

☆ Dr. Fillit on Eli Lilly's Alzheimer's drug: Really having breakthroughs & success for the first time
▼ + stars: | 2024-06-11 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDr. Fillit on Eli Lilly's Alzheimer's drug: Really having breakthroughs & success for the first timeDr. Howard Fillit, Alzheimer’s Drug Discovery Foundation co-founder and chief science officer, joins 'Squawk Box' to discuss news of FDA panel's approval of Eli Lilly's Alzheimer's drug Donanemab, the future of Alzheimer's treatments, and more.

Persons: Fillit, Eli Lilly's Alzheimer's, Howard Fillit, Eli Lilly's Organizations: Discovery Foundation, FDA

☆ A successful Alzheimer's drug will help Eli Lilly join the $1 trillion club
▼ + stars: | 2024-06-11 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Eli Lilly became the most valuable health-care company in the world on the back of its blockbuster diabetes and obesity drugs. The billions of dollars in Eli Lilly is investing in manufacturing capacity support the idea that the long-term opportunity is immense. Adding Eli Lilly to the market could help address some of the obstacles that limited Leqembi's sales early on. Eli Lilly, which has spent billions in search of a successful Alzheimer's treatment , had hoped for donanemab to be approved by now. A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana.

Persons: Eli Lilly, donanemab, Eli Lilly's, Donanemab, Leqembi —, Biogen, —, Jim Cramer's, Ken Langone, Morgan Stanley, Cantor Fitzgerald, Leqembi, Jim Cramer, Jim, Scott Olson Organizations: Food and Drug Administration, FactSet, Novo Nordisk, FDA, GE Healthcare, CNBC, Company, Getty Locations: GLP, Indianapolis , Indiana

☆ FDA advisers say Eli Lilly Alzheimer's treatment is effective
▼ + stars: | 2024-06-10 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA advisers say Eli Lilly Alzheimer's treatment is effectiveDr. Scott Gottlieb, Former FDA Commissioner, joins 'Closing Bell Overtime' to talk news that the FDA has deemed Eli Lilly's Alzheimers treatment as effective.

Persons: Eli Lilly Alzheimer's, Scott Gottlieb, Eli Lilly's Organizations: FDA

☆ FDA advisers say Eli Lilly's Alzheimer's treatment is effective
▼ + stars: | 2024-06-10 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA advisers say Eli Lilly's Alzheimer's treatment is effectiveCNBC's Angelica Peebles joins 'Closing Bell' to discuss the FDA's advisers vote on Eli Lilly's Alzheimer's drug.

Persons: Eli Lilly's, Angelica Peebles

☆ FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval
▼ + stars: | 2024-06-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. A panel of independent advisors to the Food and Drug Administration on Monday recommended Eli Lilly 's Alzheimer's drug donanemab, paving the way for the treatment to receive full approval in the U.S. later this year. If cleared for use, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the U.S. market after another treatment called Leqembi from Biogen and its Japanese partner Eisai. In a second vote, advisors unanimously said the benefits of Eli Lilly's donanemab outweigh its risks. It was another blow to Eli Lilly, which initially expected donanameb to win approval at the end of last year.

Persons: Eli Lilly, Eli Lilly's donanemab, Eisai, Eli Lilly's, Sarah Dolan, Dolan, Mark Mintun, donanameb, Leerink, David Risinger, Risinger Organizations: Food and Drug Administration, FDA Locations: Indianapolis , Indiana, U.S, Biogen, Black

☆ Fed rate cut guessing game dominates ahead of 5 major events for investors
▼ + stars: | 2024-06-07 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

Market wrap : Stocks were mixed and drifting in Friday afternoon trading. Wall Street's earlier gains Friday came despite a surge in bond yields and another pushout of Federal Reserve interest rate cut odds. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Morgan Stanley, Friday's, Eli Lilly, Lilly, Jim Cramer's, Jim Organizations: CNBC, Nasdaq, Abbott Laboratories, Nvidia, Apple, Developers, FDA, Broadcom, Jim Cramer's Charitable Locations: Wells

☆ Jim Cramer's week ahead: Fed meeting and CPI report
▼ + stars: | 2024-06-07 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Friday guided investors through next week's most market-moving events, highlighting the Federal Reserve's meeting and the latest consumer price index report. Nvidia will implement its 10-for-1 stock split, and Cramer said shares might drop on Monday as buyers take profits. Oracle reports on Tuesday, and Cramer said he's not sure how this enterprise software company will fare. Casey's General Stores will also report that day, and Cramer said business is strong and the stock has been "a total winner." In that vein, the Fed will likely leave rates higher for longer at its Wednesday meeting, Cramer said.

Persons: CNBC's Jim Cramer, Jay Powell, Eli Lilly, Cramer, Eli Lilly's, he's, hasn't, nonfarm, He'll Organizations: Nvidia, Apple, Apple's, Conference, Vision Pro, FDA, Oracle, Casey's, Broadcom, Signet, Adobe Locations: Figma

☆ Why the market is in a holding pattern, plus updates on 3 key portfolio stocks
▼ + stars: | 2024-06-06 | by ( Zev Fima | ) www.cnbc.com time to read: +3 min

One up, one down: Club stock Eaton is is down, despite being added to Jefferies' "Franchise Picks" list on Thursday. Please remember that when people get extra shares they tend to sell them, not buy them, but ultimately split stocks do well. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Mason Morfit, ValueAct, Salesforce, Eaton, Jefferies, Jim, Eli Lilly, payrolls, Jim Cramer's, Justin Sullivan Organizations: CNBC, Food and Drug Administration, Nvidia, Tech, Jim Cramer's Charitable Locations: San Francisco

☆ Alphabet's new CFO was in the middle of the GLP-1 boom. Now she's onto generative AI
▼ + stars: | 2024-06-06 | by ( Jennifer Elias | ) www.cnbc.com time to read: +10 min

Alphabet announced on Wednesday that Eli Lilly Chief Financial Officer Anat Ashkenazi will be its new CFO after an almost year-long search. Shares of Eli Lilly have soared 90% in the past year and are trading at a record. When she joined Eli Lilly in 2001, she came in through the company's new venture capital division, which was co-founded by her then-spouse Ron Laufer. Fastest growth in decadesFounded in 1876, Eli Lilly has long been one of the major U.S. pharmaceutical companies. But the last couple years have marked a period of historic growth for Eli Lilly due to the exploding popularity of GLP-1s.

Persons: Anat Ashkenazi, Eli Lilly Eli Lilly Alphabet's, Ruth Porat, Eli Lilly, Ashkenazi, it's, Eli Lilly's, David Ricks, Morgan Stanley, Sundar Pichai, Hollie Adams, Ron Laufer, John Smiley, Eli, It's, Trump, Eli Lilly's Covid, we're, Askhenazi, OpenAI's, Larry Page, Sergey Brin, CNBC's Eric Rosenbaum, Toby Lyles Organizations: San, San Francisco Bay Area, Google, Economic, Bloomberg, Getty, CNBC, Tel Aviv University, Hebrew University, U.S . Food, Drug, U.S . Department of Justice, FDA, Reuters, Employees, NBC Locations: U.S, Indiana, San Francisco Bay, Davos, Switzerland, Israel, biopharma, North Carolina, Germany, New Jersey

☆ My grandma couldn't remember my name because of dementia. It really hurt even though I know it wasn't her fault.
▼ + stars: | 2024-06-04 | by ( Nandini Maharaj | ) www.businessinsider.com time to read: +6 min

When I was 16, my grandma started to forget things like turning off the stove and mistaking sugar for salt. Memory loss is one of the earliest symptoms of dementia and is often noticed first by other people besides the affected individual. My mom would visit my grandma daily while my sister and I accompanied her on weekends. It struck me that, although she couldn't remember my name, she never forgot about the value of getting an education. Despite everything, some memories remain intactThe weekend before my 17th birthday, my grandma was receiving palliative care at a hospital for pneumonia.

Persons: —, Anand, it's, Nandini, it's Nan, I've, Nandini Maharaj Organizations: Service, Business, CDC Locations: cardigan, Trinidadian

☆ These are JPMorgan’s highest conviction stock picks over the next 12 months
▼ + stars: | 2024-05-22 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Specifically, analyst Chris Schott called Eli Lilly one of his highest conviction opinions. Analyst Harlan Sur noted that one of his top picks includes semiconductor manufacturer Broadcom , which has rallied 25% in 2024. In the report, the bank also highlighted data centers as an area that investors should watch. As demand grows for data centers, beneficiaries could include stocks such as Vertiv , up an eye-watering 106% in 2024, which is one of analyst Steve Tusa's highest conviction picks in the electrical equipment industry. Other stocks JPMorgan listed in the report include Delta Airlines and Carvana .

Persons: Chris Schott, Eli Lilly, Harlan Sur, Steve Tusa's, Rajat Gupta, — CNBC's Michael Bloom Organizations: JPMorgan, Dow Jones, Major Pharma, Broadcom, Delta Airlines

☆ Signs of Alzheimer’s were everywhere. Then his brain improved
▼ + stars: | 2024-05-18 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +16 min

Blood biomarkers of telltale signs of early Alzheimer’s disease in the brain of his patient, 55-year-old entrepreneur Simon Nicholls, had all but disappeared in a mere 14 months. “I don’t use the term ‘reverse.’ I don’t know what reverse means when it comes to the field of Alzheimer’s,” Isaacson said. ‘It was time to turn to my brain’Slowly, Nicholls’ heart condition began to improve, but the bad news didn’t end there. A brain scan found telltale signs of vascular damage in Nicholls’ brain, which occurs when the tiniest blood vessels are starved of oxygen. Not only was Nicholls blood negative for amyloid and tau, the test suggested that his brain amyloid might be normal, with no distinguishable signs of the disease.

Persons: Sanjay Gupta, Anderson Cooper ”, Richard Isaacson, Simon Nicholls, “, ”, Isaacson, “ Simon, ” Isaacson, Nicholls, ” Nicholls, Anderson Cooper, It’s, APOE4, Simon, ” Simon Nicholls, Sylver, Lewy, Richard Isaacson ‘, APOE ε4, “ I’ve, Isaacson doesn’t, “ I’m, Shocked, Dr, we’d, “ It’s, Salvadore, Richard Isaacson “, ‘ It’s, I’m Organizations: CNN, telltale, ” CNN, Boca Raton Locations: Boca Raton , Florida, New York City, Florida, Nature, Miami, Isaacson’s Florida, tirzepatide

☆ These are Goldman Sachs' favorite stocks with 50% or more upside
▼ + stars: | 2024-05-15 | by ( Weizhen Tan | ) www.cnbc.com time to read: +3 min

'Conviction list' stocks with big upside Investors still looking for quality names with more upside may want to consider names in Goldman's conviction lists — directors' cut. CNBC Pro scoured Goldman's May conviction lists for stocks with further upside of 50% or more, based on the bank's price targets. Goldman gave it a price target of $35, implying 107% upside. Goldman gave it a price target of 37 euros ($40), implying 64% upside. The bank gave the stock a price target of 380,000 Korean won ($277), or potential upside of 94%.

Persons: Stocks, Goldman Sachs, Peter Oppenheimer, Goldman, Neste, — CNBC's Michael Bloom Organizations: Dow Jones, U.S . Federal, Fed, CNBC, Europe's, Energy, Korean Locations: 1Q24, United States, Europe, Asia, Korean

☆ Not all ultra-processed foods are created equal. Here are the 4 UPFs linked with early death in a study.
▼ + stars: | 2024-05-09 | by ( Kim Schewitz | ) www.businessinsider.com time to read: +5 min

Eating certain types of UPFs carries a higher risk of early death than others, a new study found. AdvertisementPeople who eat a lot of ultra-processed foods are more likely to die early than those who don't, according to a study. Chan School of Public Health, told CNN that the association between UPFs and early death was "moderate" and not equally strong among all UPFs. Notably, a recent study linked UPFs to 32 health problems, including cancer, cardiovascular disease, and depression. To address these concerns, the researchers placed UPFs into nine groups to assess if some foods had a greater impact than others.

Persons: —, Mingyang, Harvard T.H, UPF, Gunter Kuhnle Organizations: Service, Harvard, of Public Health, CNN, University of Reading Locations: Chan, UPFs

☆ Chris Hemsworth wants you to know he doesn't have dementia and isn't retiring
▼ + stars: | 2024-04-30 | by ( Rachel Hosie | ) www.businessinsider.com time to read: +4 min

However, many people didn't understand that it wasn't an Alzheimer's diagnosis, Hemsworth told Vanity Fair. Dementia is an umbrella term to describe serious memory and thinking problems, while Alzheimer's is a specific disease that can progress into dementia. Hemsworth previously told Men's Health that he's started doing more cardio, taking more alone time, being more mindful, and prioritizing sleep. "I think for the first time in my career, I've started thinking, 'Shit, how many years do I have left that I can do this?'" "I know my dad is going through a transition of acceptance around 'I'm not this big, strong man with all the answers who everybody looks to for guidance now,'" Hemsworth told the publication.

Persons: —, Chris Hemsworth wasn't, Hemsworth, Men's, he's, I've, Hemsworth's, Craig Organizations: Service, Geographic, Business, Hemsworth, Men's Health Locations: Hemsworth

☆ GE Healthcare's disappointing first quarter offers both a lesson and an opportunity
▼ + stars: | 2024-04-30 | by ( Jeff Marks | ) www.cnbc.com time to read: +10 min

GE Healthcare shares sank Tuesday after the company's first-quarter sales and profits fell slightly short of the Wall Street consensus. GE Healthcare Why we own it : GE Healthcare is the global leader in medical imaging, diagnostics, and digital solutions in health care. That's what we have to say about this GE Healthcare quarter. This contributed to some of the softness in the first quarter quarter. The GE Healthcare scanner is called the Revolution CT. Martin Schutt | picture alliance | Getty Images

Persons: didn't, GE Healthcare's, —, it's, Peter Arduini, Jim Cramer's, Jim Cramer, Jim, Martin Schutt Organizations: GE Healthcare, LSEG, General Electric, Philips, Siemens, GE Healthcare YTD, GE, Management, Alzheimer's, CNBC, Getty Locations: China, Covid, Jena , Germany

☆ Eli Lilly assures investors it can overcome the high-quality problem of too much demand
▼ + stars: | 2024-04-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

Eli Lilly 's raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. At their highs of the morning, shares of Eli Lilly traded above their all-time closing high of $792.28 set on March 4. In general, the more-bullish financial outlook helps make Eli Lilly's high price-to-earnings ratio coming into earnings more tolerable for investors. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: Eli Lilly, Eli Lilly's, Lilly, Jim Cramer, Lilly's, Jim, Anat Ashkenazi, Zepbound, It's, Ashkenazi, Dave Ricks, donanemab, Jim Cramer's, Eli Lilly’s, Brendan McDermid Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, U.S, Drug Administration, Nexus Pharmaceuticals, CNBC, FDA Locations: Eisai, Zepbound, Trulicity, Wisconsin, New York City, U.S

☆ Why Eli Lilly's earnings are no sure thing for traders despite obesity drug momentum
▼ + stars: | 2024-04-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Tirzepatide is the active ingredient in both Eli Lilly's diabetes treatment Mounjaro and its anti-obesity drug Zepbound. Based on that calculation, earnings will be lower by about 13 cents per share, he said, in research published last Tuesday. "Strong demand for Mounjaro & Zepbound can easily pull through in 2H24 and make up for any 1H24 shortfalls." For the week ended April 19, combined prescriptions of Mounjaro and Zepbound rose 63% year over year, according to IQVIA. Wells Fargo Mohit Bansal said he expects investors to look past any Trulicity shortfalls as the focus is firmily on Zepbound and Mounjaro for Lilly's future growth.

Persons: Eli Lilly, Eli, James Shin, Lilly, Shin, David Risinger, Zepbound, Wells, Bansal, Jo Walton, Walton, Lilly's, Tirzepatide, Deutsche Bank's Shin, — CNBC's Michael Bloom Organizations: Drug Administration, Deutsche Bank, IMS, UBS, Research, Deutsche, FDA Locations: 2H24, U.S

☆ Cramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli Lilly
▼ + stars: | 2024-04-26 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

It's a week jam-packed with notable events, including earnings from Apple , Amazon and Eli Lilly . He also said to pay attention to Wednesday's Federal Reserve meeting and Friday's employment figures from the Department of Labor. "We have to run such a ridiculous gauntlet next week that I have no idea how it'll play out," he said. Wednesday also brings reports from Wingstop , Carvana and Marriott . Apple will report on Thursday, and Cramer noted there's been a lot of negative sentiment from investors surrounding the company.

Persons: CNBC's Jim Cramer, Eli Lilly, Jensen Huang, Cramer, it's, he'll, Seagen, there's Organizations: Apple, Federal Reserve, Department of Labor, Nvidia, Food and Drug Administration, Starbucks, CVS, Pfizer, Amazon, Walgreens, Marriott, Vision Locations: It's, China, Wingstop, Carvana

☆ Biogen tops profit estimates as cost cuts take hold, Alzheimer's drug Leqembi launch picks up
▼ + stars: | 2024-04-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Biogen on Wednesday reported first-quarter profit that topped estimates as the company's cost-cutting efforts took hold and sales of its closely watched Alzheimer's drug, Leqembi, came in higher than expected. Biogen and Eisai 's Leqembi became the first drug found to slow the progression of Alzheimer's disease to win approval in the U.S. in July. Leqembi brought in about $19 million in sales for the quarter, up from the $10 million the drug generated last year. In February, Biogen CEO Chris Viehbacher told reporters that there were around 2,000 patients currently on Leqembi. Adjusting for one-time items, the company reported earnings of $3.67 per share.

Persons: Biogen, Leqembi, FactSet, Chris Viehbacher, LSEG Organizations: LSEG Locations: U.S

Search resuls for: "Alzheimer's"

25 mentions found